Tillkännagivande • 18h
Oxford Nanopore Technologies plc Announces Executive Appointments Oxford Nanopore Technologies plc announced the appointments of Davide Manissero MD as Chief Medical Officer and Andrew Watson as Chief Information Officer. As Oxford Nanopore's first Chief Medical Officer, Davide will lead the Company's global clinical strategy leveraging his considerable experience across regulated clinical environments. Davide joins from Radiometer (a Danaher company), where he is currently CMO. He previously served as CMO at QIAGEN, leading global medical and clinical affairs, and held roles at ECDC and the WHO focused on infectious diseases and public health. Andrew Watson will lead the Company's information systems, data, digital transformation, machine learning, and product software development. Andrew joins from Mimecast, where he leads AI and threat protection engineering. He has previously held senior roles at Healx and Dyson, where he established machine learning and biomedical research teams. Andrew Watson and Davide Manissero join the Company on June 15, 2026 and August 3, 2026 respectively. Their appointments follow the announcement that Tina St Leger will join Oxford Nanopore as Chief People Officer in June 2026. Davide, Andrew and Tina will join the Executive team. In accordance with UK Listing Rule 6.4.6(3), the Company notes that responsibility for the commercial function will transfer from Nick Keher, CFO, to Francis Van Parys, CEO, effective 1 July 2026. Tillkännagivande • May 22
Oxford Nanopore Technologies plc Presents Technology Update At Annual Customer Conference Oxford Nanopore Technologies plc presented a Technology Update at the Company's flagship annual London Calling customer conference. Opening London Calling 2026, the Company highlighted continued focus on customer-led platform development, strengthening the user end-to-end experience and supporting broader adoption in applied and regulated environments. At the Annual Technology Talk the Company highlighted updates including: Platform development led by customer need. Delivering richer multiomic insight from a single platform: advances in integrated DNA, RNA and epigenetic data, including methylation, providing comprehensive insight from a single system. Driving continuous improvement in platform performance, including accuracy, base modifications, output and speed, with continued enhancement of unique features such as adaptive sampling. This includes the introduction of the PromethION Plus Flow Cell, designed to increase output with enhanced yield achieved without additional wash and reload steps. The Company also highlighted increasing use of AI-driven methods across basecalling, variant detection and downstream analysis. Expanding platform capability across core workflows, including transcriptomics (RNA), microbial and vaccine QC (GridION Q), and high-output sequencing (PromethION), with new chemistry and workflows shipping from May to July 2026. Regulatory readiness. Advancing reliability and consistency: improvements in repeatability and robust performance in production environments, enabling predictable use at scale. Expanding real-world deployment across routine and regulated settings. End-to-end experience. Simplifying workflows and reducing complexity to support broader adoption. Advancing integrated software platforms, including EPI2ME, for accessible and standardised data interpretation. Longer-term innovation and platform pipeline. Continuing investment across chemistry and hardware towards both low and high output applications, and development of multiomic capability including protein sequencing, extending the platform into new areas of biological insight. Showcasing a novel demonstration of peptide sequencing using an amino-acid calling for accurate protein identification. A video replay of the Technology Talk is available on the Oxford Nanopore website. Tillkännagivande • May 02
Oxford Nanopore Technologies plc, Annual General Meeting, Jun 04, 2026 Oxford Nanopore Technologies plc, Annual General Meeting, Jun 04, 2026. Location: the companys offices at gosling building, edmund halley road, oxford science park, oxford, ox4 4dq, United Kingdom Tillkännagivande • Mar 03
Oxford Nanopore Technologies plc Provides Earnings Guidance for the Year 2026 Oxford Nanopore Technologies plc provided earnings guidance for the year 2026. For the year, the company expects revenue is expected to grow by 21-25% on a constant currency basis. Gross margin is expected to be approximately 62%, driven by continued operational improvements (flow cell recycling) and tailwinds from the changes to the pricing model. Tillkännagivande • Nov 08
Oxford Nanopore Technologies plc Reaffirms Earning Guidance for the Full Year 2025 Oxford Nanopore Technologies plc reaffirmed earning guidance for the full year 2025. For the period, the company expects full-year 2025 constant currency revenue growth to be at the top end of its previously stated guidance range of 20-23%, with all other financial metrics tracking in line with expectations. Tillkännagivande • Nov 06
Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis Oxford Nanopore Technologies plc and bioMérieux have announced the launch of AmPORE-TB, a Research Use Only (RUO) solution for the rapid characterization of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis complex, using Oxford Nanopore sequencing technology. While preventable and treatable, the World Health Organization considers tuberculosis (TB) the world's leading cause of death from a single infectious agent i. Multidrug-resistant TB affects about 400,000 people annually and increases risk of morbidity and mortality ii. To address this public health crisis, WHO points out the need for rapid, reliable antimicrobial susceptibility tests. WHO has recommended targeted DNA sequencing, with AmPORE-TB named as one of three targeted methods meeting the class-based performance criteria for the detection of AMR gene mutations iii. Available for research use only, AmPORE-TB is a complete solution, which uses Oxford Nanopore's benchtop dedicated GridION device to characterize 24 TB-resistant genes and provides comprehensive results within the same day. With its built-in software, the solution provides automated data analysis and reporting. The WHO recognition underscores the importance of the AmPORE-TB technology, which can provide rapid, high-resolution insights into the genetic makeup of drug-resistant tuberculosis. The solution is designed and manufactured by Oxford Nanopore and distributed by bioMérieux*. AmPORE-TB is expected to be launched first in the regions with the highest need and where it can add the most value, including low- and middle-income countries, where 99% of new cases occur. Tillkännagivande • Oct 15
Oxford Nanopore Technologies Announces PromethION Plus Flow Cell and Human Genetics Updates At ASHG 2025 At the American Society of Human Genetics (ASHG) 2025 industry session on 16th October, Oxford Nanopore Technologies will share its latest developments in enabling translational and clinical human genetics communities to deliver improved insights into mechanisms for disease in one integrated analysis. The team will highlight the unique capabilities of the PromethION in delivering comprehensive whole genomes and methylomes, alongside transformational, information-rich targeted assays using Adaptive Sampling. By delivering fully comprehensive genomic insights, Oxford Nanopore customers are deploying the technology in translational clinical settings to solve diagnostic odysseys in rare disease, enhance cancer characterisation, and drive novel discoveries in common complex disease. Oxford Nanopore will introduce the PromethION Plus Flow Cell - a new ultra-high-output flow cell designed to deliver increasingly cost effective, comprehensive genomes and methylomes. At ASHG, Oxford Nanopore will share a series of updates that support the human genetics and translational research communities. These advances expand access to rapid, information-rich genomic and epigenomic analysis through new workflows and targeted sequencing solutions, including: The use of adaptive sampling for targeted sequencing -a fast and flexible method to enrich regions of interest that is unique to Oxford Nanopore, eliminating the need for laborious and time intensive optimisations in common capture methods. Multiple applications include: A hereditary cancer panel that interrogates 258 genes associated with inherited cancer risk and enables laboratories to speed up sample-to-answer; Rapid tumour methylation profiling; Comprehensive pharmacogenomics panels; Launch of a 24-hour workflow for comprehensive human genome analysis, that delivers sample-to-answer insights in a single day, supporting critical research in Neonatal Intensive Care Units (NICUs) and enabling rapid and comprehensive genomic insights in rare disease. PromethION Plus Flow Cells for fully comprehensive, cost-effective human genomes and methylomes. PromethION Plus will deploy an improved flow cell chemistry designed to deliver high data output, enhanced consistency, and value for high throughput human research applications - without the need for flow cell washing. Delivering comprehensive genomic and epigenetic data, PromethION Plus Flow Cells will uniquely be delivered at scale on the PromethION 24 device. This marks an important step toward multiplexing multiple genomes per PromethION Flow Cell, providing a clear pathway to significantly reducing the cost of premium, fully comprehensive, scaled human genomes and epigenomes below $345 (at 30x coverage), and beyond with future chemistry upgrades on the development roadmap. PromethION Plus Flow cells will be introduced in limited release in fourth quarter 2025, with broader availability in 2026. The new flow cells benefit all human genetics applications where comprehensive genomic and epigenetic data is required at scale. This includes discovery within population-scale studies, as well as high-throughput characterisation of clinical samples, such as those analysed in rare disease or cancer. Optimised for use with 15-30 kb fragment libraries, PromethION Plus Flow Cell will deliver high output, rich sequencing data for robust and reliable calling of a broad range of genetic variants, including methylation. Users can expect: Significantly increased flow cell output with large fragment libraries (>15kb); Reduced hands-on-time with no wash protocols (15kb libraries); Lower input requirements; Best value per 30x genome for high throughput sequencing customers; Prepares the platform for faster kit chemistry to deliver further output improvements planned for 2026. Tillkännagivande • Aug 13
Oxford Nanopore Technologies plc Announces Step Down of Gordon Sanghera Notifies as Chief Executive Officer by the End of 2026 Oxford Nanopore Technologies plc announced that Gordon Sanghera has notified the Board of his intention to step down as Chief Executive Officer (CEO) and from the Board by the end of 2026, after more than 20 years in the role. As part of a long-standing succession planning process, the Board has now commenced a formal search for a successor to lead the Company through its next phase of growth and commercialisation. Gordon co-founded Oxford Nanopore in 2005 and has served as CEO since its inception, leading the development and commercialisation of its pioneering nanopore-based sensing technology. Under his leadership, the Company set out to transform molecular analysis by delivering richer biological data faster, more affordably, and more accessibly than legacy technologies. This vision began to materialise with the launch of the MinION in 2015, the world's first portable sequencing device, and has since evolved into a broad portfolio of devices serving customers in over 125 countries across both Research and Applied markets. The impact of Oxford Nanopore's technology is reflected in more than 14,000 peer-reviewed publications and sustained, above-market growth. In recognition of his role in advancing technologies that have had global scientific and medical impact, Gordon was appointed Commander of the Most Excellent Order of the British Empire (CBE) in the 2023 New Year Honours. Tillkännagivande • Aug 07
ViruSure Launches Pioneering First-In-Class Viral Contamination Test for Biopharmaceuticals Using Oxford Nanopore Technology ViruSure and Oxford Nanopore Technologies plc announce the launch of the industry’s first Good Laboratory Practice (GLP) validated adventitious viral agent (AVA) detection test using nanopore-based sequencing technology.
The ViruSure test has been developed and evaluated under rigorous conditions and is powered by Oxford Nanopore’s advanced molecular sensing platform. It will be used for the detection of viral contamination within the manufacturing process, providing biopharmaceutical teams with richer viral detection insights and faster time-to-result, accessibly and affordably. A rapid and sensitive test, it can detect AVAs regardless of virus type, to improve confidence in biomanufacturing safety. Viral contamination remains one of the most significant threats to biopharmaceutical manufacturing, causing production delays and potential biologic, vaccine and cell and gene therapy product shortages. Traditional viral detection methods can take months to provide the full panel of results, with each individual test often taking more than 14 days, and contaminants still going undetected or reported as false positives. This innovation addresses a critical need to streamline AVA detection within biomanufacturing, a rapidly growing market currently valued at $20 billion, of which at least $4 billion is related to AVA testing. Global regulatory authorities have also recognised the urgent industry demand for faster and more reliable solutions and actively encouraged the adoption of advanced sequencing-based testing methods. ViruSure and Oxford Nanopore are also working together to introduce a Good Manufacturing Process (GMP)-validated solution, which they expect will follow shortly. Tillkännagivande • Jun 06
Oxford Nanopore Technologies plc Announces Remuneration Committee Changes Oxford Nanopore Technologies plc announced that Heather Preston has been appointed as Chair of the Remuneration Committee with effect from 5 June 2025. Heather has been a Non-Executive Director of the Company since December 19, 2023, and is also a member of the Nomination Committee. Heather succeeds John O'Higgins, who stands down as Interim Chair of the Remuneration Committee but remains a member of the Remuneration Committee, Nomination Committee, and Audit & Risk Committee. Tillkännagivande • May 22
Oxford Nanopore Technologies plc Presents Technology and Platform Updates Oxford Nanopore Technologies plc presented technology and platform updates at the Company's annual London Calling customer conference. During the sold-out event, with more than 4,500 registered online and in-person participants from more than 120 countries, the Company also provided updates to its long-term innovation pipeline. Technology and pipeline updates included: Continued enhancement to product performance, reliability and competitiveness: The presentation highlighted the development of high throughput workflows, flow cell improvements and new kit chemistries to drive higher output on the PromethION Flow Cell. Improved analytics and insights for broad applications: Continued development of EPI2ME, the Company's informatics platform which provides analysis tools for a growing menu of end-to-end workflows. Updates included (i) a new high-performance variant caller to increase consistency and accelerate workflows, especially in production environments where speed and reproducibility are key drivers and (ii) continued development of base modification calling, with more than ten modifications now supported. This enables improved accuracy of methylation detection, without the need for complex processes required with legacy sequencing technologies. Improving direct RNA sequencing, to accelerate biopharma workflows with a single streamlined platform: Recent updates to the cDNA kit and direct RNA workflows enable longer reads and higher output, delivering performance supporting biopharma applications beyond mRNA Vaccine Quality Control, including drug discovery, sterility testing, and exploring tissue-specific RNA modifications. Near term focus on regulated product pipeline to driving adoption in applied markets: The GridION Q device is expected to complete CE-IVD submission in the EU for regulated clinical markets by the end of 2025. The device will be available for specified partners only. The Q-Line product range is expanding to include PromethION Q, now expected to launch in 2026, to broaden the opportunity for human sequencing applications. Am ambitious and targeted long-term innovation pipeline: including the ongoing development of a new voltage-controlled ASIC for high throughput customers. A roadmap to proteomics: Oxford Nanopore is now making advancements into providing solutions for protein analysis, a key area for scientific research and discovery in health and substantial potential for applied uses in clinical and industrial applications. The Company is currently developing two complementary approaches: one focused on identifying native proteins in clinical samples, and another designed for scalable protein barcoding. Both workflows are in development, with future potential to enable the direct detection and characterisation of full-length proteins. A detailed written summary and a video replay of the technology talk can be accessed on the Oxford Nanopore website here. Tillkännagivande • Apr 30
Oxford Nanopore Technologies plc, Annual General Meeting, Jun 04, 2025 Oxford Nanopore Technologies plc, Annual General Meeting, Jun 04, 2025. Location: the companys offices at gosling building, edmund halley road, oxford science park, ox4 4dq, oxford United Kingdom Tillkännagivande • Mar 04
Oxford Nanopore Technologies plc Provides Earnings Guidance for the Year 2025 Oxford Nanopore Technologies plc provided earnings guidance for the year 2025. For the year, the company expects revenue to grow by 20% to 23% on a constant currency basis, reflecting continued strong demand across the business but taking into consideration recent updates and risks to US Federal funding, in particular with the National Institutes of Health (NIH), and a tightening of export control restrictions: Federal funding including the NIH: there remains material uncertainty and risk to US NIH funding levels (and other Federal agencies) to which management estimate a total Group exposure of between 10% to 15% of revenues. Given the situation is still evolving, management have prudently assumed a material reduction pending further clarity. Tillkännagivande • Dec 17
Oxford Nanopore Technologies plc Appoints Kate Priestman as Senior Independent Director Oxford Nanopore Technologies plc announced that Kate Priestman has been appointed as Senior Independent Director with immediate effect. Kate has been a Non-Executive Director of the Company since 13 July 2023 and is a member of the Remuneration and Nomination Committees. Tillkännagivande • Dec 16
Oxford Nanopore Technologies plc to Report Fiscal Year 2024 Results on Mar 04, 2025 Oxford Nanopore Technologies plc announced that they will report fiscal year 2024 results on Mar 04, 2025 Tillkännagivande • Nov 11
Oxford Nanopore Technologies plc Announces Executive Changes Oxford Nanopore Technologies plc announced that Rosemary Sinclair Dokos has been appointed as Chief Product and Marketing Officer and Dr Lakmal Jayasinghe has been appointed as Chief Scientific Officer, effective immediately. Rosemary and Lakmal, who will report to Chief Executive Officer Dr Gordon Sanghera, succeed Clive Brown, Chief Officer of Technology, Innovation, and Products, who has stepped down to pursue new projects. Clive will be available to the business on an advisory basis to support an effective transition. Rosemary has more than 18 years' experience in innovation, including product management and commercial functions. She joined Oxford Nanopore in 2014 andhas been apivotal force in driving the Company's product strategy and execution, overseeing the development of Oxford Nanopore's platform technologies, including the recent PromethION 2 and GridION Q-Line launches. In her new role, Rosemary will continue leading the development of products that include new multiomic, clinical, biopharma and industrial applications, in addition to platform technology innovations and marketing. Lakmal is a highly respected, world-leading nanopore and protein sensing scientist and scientific leader, with more than 18 years' experience. He joined Oxford Nanopore in 2007 andhas been responsible for all biological research and development projects at Oxford Nanopore.Lakmal will continue to lead efforts to integrate new multiomic capabilities, including genomics, transcriptomics, proteomics, and metabolomics, into the Company's platform. Tillkännagivande • Oct 01
Oxford Nanopore Technologies plc Appoints Daniel Mahony as A Non-Executive Director Oxford Nanopore Technologies plc announce that Dr Daniel Mahony will be joining the Group as a Non-Executive Director with effect from 1 October 2024. Daniel brings extensive sector experience to help accelerate Oxford Nanopore's commercial traction, with more than 25 years as a global healthcare investor specialising in biotechnology, medical technology and healthcare services. As Senior Partner in Growth Investments at Novo Holdings, Daniel will serve as a critical sounding board to the Group as it continues to advance its technology platform to address a significant commercial opportunity in biopharmaceuticals. In addition, he currently chairs the UK BioIndustry Association and is a Non-Executive Director of the Wellcome Sanger Institute. Prior to joining Novo Holdings, Daniel co-founded the healthcare business unit at Polar Capital in London, growing it to more than $4 billion in assets under management. He was formerly a Senior Research Analyst at Morgan Stanley in London, an Analyst at ING Barings Furman Selz in New York, and completed his postdoctoral work at DNAX Research Institute in Palo Alto. Dr Guy Harmelin, a non-executive director of the Group, who has served on the Board since 2020, has informed the Board of his intention to step down from the Board with effect from today. Dr Guy Harmelin, is stepping down to focus on various other Directorship responsibilities. Tillkännagivande • Jun 13
Oxford Nanopore Technologies plc Announces Changes to Director Oxford Nanopore Technologies plc at its AGM held on June 10, 2024, announces that John O'Higgins, a Non-Executive Director, has been appointed Chair of the Remuneration Committee on an interim basis with effect from June 10, 2024. As previously disclosed, Tim Cowper, Dr Spike Willcocks, and Wendy Becker, the previous Chair of the Remuneration Committee, stepped down from the Board at the conclusion of the Company's Annual General Meeting earlier June 10, 2024. Tillkännagivande • May 24
Oxford Nanopore Technologies plc Provides Updates to its Clinical Product Pipeline Oxford Nanopore Technologies plc provided updates to its clinical product pipeline, unveiling a new roadmap for its first IVD product ahead of its first clinical and biopharma day.Technology updates included: Delivering increasingly rich, high performance multiomic data: The update focused on improved performance on accuracy, delivering complete genomes with nanopore-only Telomere-to-Telomere (T2T) sequencing, and full-length chromosomes in a single read, illustrated by successful T2T reads of four yeast chromosomes as proof of concept. Improving direct RNA sequencing to support breakthrough science and biopharma workflows: higher accuracy and output for direct RNA sequencing alongside the example of integrated, real-time quality control (QC) test for mRNA vaccines. Pipeline updates, enabling ultra-high output and accessible, distributed sequencing for anyone, anywhere: with the MinION Mk1D entering early access, continued progression with TraxION, enabling portable library prep in the field, the Voltage chip for ultra-rapid whole genome sequencing (WGS)and the new prototype of Oxford Nanopore's smallest sequencer to date - the SmidgION - which was on display at the event. Tillkännagivande • May 03
Oxford Nanopore Technologies plc to Report First Half, 2024 Results on Sep 03, 2024 Oxford Nanopore Technologies plc announced that they will report first half, 2024 results on Sep 03, 2024 Tillkännagivande • Apr 01
Oxford Nanopore Technologies plc, Annual General Meeting, Jun 10, 2024 Oxford Nanopore Technologies plc, Annual General Meeting, Jun 10, 2024. Tillkännagivande • Mar 08
Oxford Nanopore Technologies plc Provides Earnings Guidance for the Year 2024 Oxford Nanopore Technologies plc provided earnings guidance for the year 2024. The company expects full year 2024 LSRT revenue of between 6% to15% growth on a constant currency basis, equating to £180 million to £195 million at current exchange rates which is 20% to 30% growth on an underlying basis, when excluding known headwinds from COVID sequencing of approximately £8 million as well as a year-over-year headwind of up to £12 million from the revised amendment to the Group's agreement with G42 in supply of sequencing tools in support of the EGP. EGP and COVID sequencing are not expected to contribute meaningfully to group revenue in 2024 and as such any revenue will be reported as underlying growth from 2024 onwards. Revenue growth of more than 30% on a compound annual growth rate at constant currency between fiscal year 2024 and fiscal year 2027, in-line with historical performance. Tillkännagivande • Mar 07
Oxford Nanopore Technologies Launches PromethION 2 Integrated into Open Early Access Oxford Nanopore Technologies announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete its PromethION product range. Engineered with robust and powerful onboard computing capabilities, the P2i facilitates real-time basecalling and post run analysis directly within the device, eliminating the dependency on external computing resources. The self-contained device delivers up to 290 Gb of data per flow cell from native DNA, RNA or cDNA libraries, and utilises onboard NVIDIA Ampere architecture to deliver the higher quality raw-read data in real-time. Each flow cell will be capable of delivering the lowest price per Gb for Oxford Nanopore sequencing, providing a rapid and convenient solution for achieving the coverage required for sequencing larger genomes. The in-built touchscreen provides flexibility and convenience for users, while seamless integration with the MinKNOWTM sequencing software ensures the device is ready to work immediately out of the box, significantly streamlining the sequencing process. The P2i builds upon the success of the P2 Solo, which launched in October 2022, and leased or sold over 700 units. While the P2 Solo opened the door to high coverage nanopore sequencing for small to medium sized labs, the P2i will additionally provide on-board analysis, to deliver rapid answers in real-time. This device continues to democratise high-quality, information-rich sequencing and is the ideal solution for researchers across a spectrum of multiomic studies. From sequencing large genomes of plants and animals, to conducting comprehensive metagenomic studies and facilitating cost-effective, full-transcript-length sequencing, the P2i stands as a testament to versatility and efficiency. Tillkännagivande • Mar 01
Oxford Nanopore Technologies plc Announces Directorate Change Oxford Nanopore Technologies plc announced the retirement of three Directors from the Board: Dr. James ("Spike") Willcocks, Clive Brown, and Tim Cowper. Clive will step off the Board with immediate effect while Spike and Tim will not stand for re-election at the 2024 AGM and will retire from the Board at the conclusion of the AGM in June 2024. All three Directors will remain in their operational leadership roles at Oxford Nanopore: Spike as Chief Strategy Officer, Clive as Chief Technology, Innovation and Product Officer and Tim as Chief Operating Officer. Each will also continue to serve on the Company's Operating Committee. Spike has served on the Board for 18 years and Clive and Tim have each served for five years. Oxford Nanopore is committed to Board diversity, and this evolution will also progress towards fulfilling the Company's goal of reaching 40% female Board representation. Following the AGM, the Board will include two executive Directors and seven non-executive Directors, three of whom are women. Tillkännagivande • Jan 09
Oxford Nanopore Technologies plc Provides Earnings Guidance for the Year 2023 Oxford Nanopore Technologies plc provided earnings guidance for the year 2023. The Group expects to report LSRT revenue for the 12 months ended 31 December 2023 of approximately £169 million (FY22: £146.8 million), representing year-on-year growth of approximately 15% on a reported basis and 15% on a constant currency basis. Underlying LSRT revenue growth, excluding revenue from Emirati Genome Program ("EGP") and COVID-19 sequencing, is expected to be approximately 39% on a constant currency basis. Strong performance across the broader customer base in FY23 was driven by consumables sales, which accounted for approximately 75% of revenue. Underlying revenue growth in the second half is expected to be approximately 32%, impacted by slower than expected ramp up of certain new S3 customers. Expected revenue from these customers in FY23 will now fall into FY24. In addition, there was some slow-down in growth in China and in the Middle East following issuance of the recent US semiconductor trade rule further regulating sales of advanced AI semiconductors. Product development plans within 2024 include updates that are expected to mitigate this headwind. Tillkännagivande • Jan 06
Oxford Nanopore Technologies plc to Report Fiscal Year 2023 Results on Mar 06, 2024 Oxford Nanopore Technologies plc announced that they will report fiscal year 2023 results on Mar 06, 2024 Tillkännagivande • Dec 19
Oxford Nanopore Technologies plc Announces Board Changes Oxford Nanopore Technologies plc announced that Dr Sarah Fortune and Dr Heather Preston will be joining the Group as Non-Executive Directors with effect from 19 December 2023. Sarah Gordon Wild and Wendy Becker, both non-executive directors of the Company, announced their retirement from Board, with effect from 19 December 2023 and at the conclusion of the AGM in 2024, respectively. As a Professor of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health in Boston, Dr Sarah Fortune brings deep expertise in genomic diagnostics and multi-omics approaches to infectious disease, including at the intersection of human genetics. Her world-leading research has focused on understanding how Tuberculosis (TB) mutates to become drug resistant using a combination of single cell, genetic, and genomic approaches, including nanopore sequencing. In 2019, she led one of three labs awarded funding by the US National Institutes of Health to establish a new center for immunology research to accelerate progress in TB vaccine development - work that remains ongoing. Oxford Nanopore will draw on Sarah's rich experience as the company seeks to develop more sequencing-based applications in the clinical space, including its first sequencing-based test for drug-resistant TB. Sarah holds a Doctor of Medicine from Columbia University and a Bachelor of Science in biology from Yale University. Heather joins the board at a time when Oxford Nanopore's platform and its latest Q20+ chemistry have delivered profound developments in system performance, including accuracy and data yield, positioning it for ambitious growth. She brings more than 30 years of experience in healthcare, as a scientist, physician, McKinsey management consultant and long-time investor in biotech and the life sciences, most recently as a Managing Partner of Pivotal BioVentures based in San Francisco. She has been a director of more than 18 private and public technology-based healthcare companies, where she was involved in designing and implementing effective scaling strategies. Oxford Nanopore will draw on her expertise as it looks to deliver long-term growth and shareholder value. Heather currently sits on the Boards of Oxford Biomedica plc, Oxford Science Enterprises plc and Azura Opthalmics. Heather holds a Doctor of Medicine from the University of Oxford and a Bachelor of Science degree in biochemistry from St Bartholomew's Hospital Medical School at the University of London. Sarah Gordon Wild, a non-executive director of the Company and the non-executive responsible for workforce engagement, will retire from the Oxford Nanopore Board with effect from 19 December 2023, having served for nine years. Kate Priestman will succeed Sarah as the non-executive director responsible for workforce engagement. Wendy Becker, a non-executive director, has informed the Board that she will not stand for re-election at the next AGM but will remain a committed supporter of the Company. Tillkännagivande • Aug 25
Oxford Nanopore Technologies Launches Pilot Accessible Sequencing Education Programme Oxford Nanopore Technologies announced the launch of “Education beta”, its pilot education programme and the first of its kind in the world delivering nanopore sequencing into the global education sector, with the aim to increase life science literacy for the next generation. The pilot will include up to 50 scientists wishing to use sequencing for scientific education in high school or undergraduate settings. Under the Education Beta programme a new community will be built to bring individuals together, give access to education-based pricing for a focused range of products, and facilitate a peer-to-peer network to develop further ideas for nanopore sequencing in education at undergraduate level and below. Tillkännagivande • Jul 17
Oxford Nanopore Technologies plc to Report First Half, 2023 Results on Sep 06, 2023 Oxford Nanopore Technologies plc announced that they will report first half, 2023 results on Sep 06, 2023 Tillkännagivande • Jul 14
Oxford Nanopore Technologies plc Appoints Kate Priestman as Non-Executive Director Oxford Nanopore Technologies plc announced that Kate Priestman will be joining the Group as Non-Executive Director with effect from 13 July 2023. Kate brings extensive experience as a biopharma executive for more than 25 years, serving in leadership roles across commercial, operations, corporate strategy, communications and government affairs. She was most recently Senior Vice President of R&D Strategy, Portfolio and Operations at GlaxoSmithKline, where she led the evolution of GSK's science and technology strategy, portfolio management and global R&D operations & business transformation, helping steer the FTSE 100 company's growth. Kate also served on GSK's separation board, delivering the successful spin-out of Haleon plc in 2022. In addition, she previously held global and UK roles at Eli Lilly & Co and Zeneca, after an early career at the BBC, where she spent several years as a broadcaster. Kate also currently also serves as a Trustee of RBG Kew, an organisation with around 500 scientists working globally to understand plant biology and fight biodiversity loss. 
